



# HHS Public Access

Author manuscript

*Genes Immun.* Author manuscript; available in PMC 2017 March 01.

Published in final edited form as:

*Genes Immun.* 2016 September ; 17(6): 349–357. doi:10.1038/gene.2016.31.

## Analysis of *Ly49* gene transcripts in mature NK cells supports a role for the Pro1 element in gene activation, not gene expression

Matthew V. McCullen<sup>1</sup>, Hongchuan Li<sup>2</sup>, Maggie Cam<sup>3</sup>, Shurjo K. Sen<sup>4</sup>, Daniel W. McVicar<sup>1</sup>, and Stephen K. Anderson<sup>1,2,\*</sup>

<sup>1</sup>Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, USA

<sup>2</sup>Basic Science Program, Leidos Biomedical Research Inc., Frederick National Lab, Frederick MD 21702, USA.

<sup>3</sup>Office of Science and Technology Resources, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA

<sup>4</sup>National Human Genome Research Institute, NIH, Bethesda, MD 20892, USA.

### Abstract

The variegated expression of murine *Ly49* loci has been associated with the probabilistic behavior of an upstream promoter active in immature cells, the Pro1 element. However, recent data suggests that Pro1 may be active in mature NK cells and function as an enhancer element. To directly assess if Pro1 transcripts are present in mature *Ly49*-expressing NK cells, RNA sequencing of the total transcript pool was performed on freshly isolated splenic NK cells sorted for expression of either *Ly49G* or *Ly49I*. No Pro1 transcripts were detected from the *Ly49a*, *Ly49c* or *Ly49i* genes in mature *Ly49*<sup>+ve</sup> NK cells that contained high levels of Pro2 transcripts. Low levels of *Ly49g* Pro1 transcripts were found in both *Ly49G*<sup>+ve</sup> and *Ly49G*<sup>-ve</sup> populations, consistent with the presence of a small population of mature NK cells undergoing *Ly49g* gene activation, as previously demonstrated by culture of splenic NK cells in IL-2. *Ly49* gene reporter constructs containing Pro1 failed to show any enhancer activity of Pro1 on Pro2 in a mature *Ly49*-expressing cell line. Taken together, the results are consistent with Pro1 transcription playing a role in gene activation in developing NK, and argue against a role for Pro1 in *Ly49* gene transcription by mature NK cells.

### Keywords

RNA Seq; mouse NK; *Ly49*; transcription

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Corresponding author: [andersonst@mail.nih.gov](mailto:andersonst@mail.nih.gov).

The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Conflict of Interest

The authors declare no conflict of interest.

## Introduction

Natural killer (NK) cells are an important element of the immune system allowing for a rapid and innate response against virally infected and tumor cells<sup>1</sup>. The NK cell cytotoxic response is controlled by a balance of activating and inhibitory signals. In mice, the C-type lectin-related Ly49 receptor family is a major mediator of these signals<sup>2</sup>. These receptors detect the absence or alteration of specific major histocompatibility complex class I (MHC I) molecules found on most healthy cells. Ly49 receptors are expressed in a variegated and stochastic manner, generating a repertoire of NK cells displaying different combinations of Ly49 receptors, which allows for the detection of deviations in the expression of specific MHC I molecules.

This receptor variegation is achieved at the transcriptional level through the interplay of multiple promoters. The selective activation of *Ly49* genes is regulated by Pro1<sup>3</sup>, a promoter upstream of the core Pro2<sup>4, 5</sup> and Pro3<sup>6</sup> promoters responsible for the production of Ly49-coding transcripts. The Pro1 promoter is bidirectional, capable of transcribing in either the sense or antisense direction in a probabilistic manner that is controlled by the relative strength of competing transcription-factor binding sites<sup>7</sup>. Forward transcription from Pro1 produces a spliced sense transcript that traverses the downstream promoter regions, and may play a role in opening up the chromatin of the Pro2 and Pro3 promoters to allow gene transcription. Reverse transcription yields noncoding antisense transcripts that likely play no active role in silencing the gene, as deletion of the Pro1 region in *Ly49* transgenes results in no detectable Ly49 expression, indicating that silence is the default state<sup>8</sup>. The variegated expression of *Ly49* genes appears to be regulated primarily at the chromatin level, with expressed genes showing increased acetylation at H3K9 and at multiple residues of H4 in the Pro2 region<sup>9, 10</sup>. Regulation by DNA methylation is unlikely, due to a low level of CpG residues in the Pro2 region.

Although initial studies of the *Ly49a* gene identified a single transcriptional start site (TSS) at Pro2<sup>11</sup>, additional studies suggest that there is no single TSS but rather that transcription can begin at various sites within major transcriptional regions throughout the *Ly49* genes<sup>6, 12</sup>. Recent studies of the *Ly49* loci have challenged the traditional view of promoters, as transcriptional start sites for the variegated *Ly49* genes were not generally found to be associated with regions possessing transcriptional activity in *in vitro* promoter assays<sup>12</sup>. Traditional promoters were identified in genes not associated with probabilistic expression, including the activating *Ly49d* and *h* genes as well as the non-NK genes *Ly49b* and *q*, suggesting that probabilistic expression may be connected with the lack of clearly defined promoter elements. The Pro1 upstream promoter element found in variegated *Ly49* genes was shown to be active in mature NK cells and function as an enhancer element, suggesting that it may play a role in *Ly49* transcript initiation in mature NK cells<sup>13</sup>.

In the current study, we assess the total *Ly49* transcriptional landscape of mature Ly49-expressing NK cells by RNA sequencing, revealing that Pro1 transcripts are very rare in mature NK cell populations, and further demonstrate that Pro1 lacks enhancer activity. We also investigate the unusual properties of the *Ly49i* gene, characterizing a novel *Ly49i*

promoter (designated Pro2<sup>1</sup>) preceding exon -1b and identifying rare antisense transcripts originating from the core promoters Pro2 and Pro3.

## Results

### RNA sequencing of sorted Ly49G versus Ly49I-expressing splenic NK cells

The majority of previous studies of RNA expression by murine splenic NK cells have made use of gene arrays to assay gene expression profiles, and are therefore lacking information with regard to promoter utilization, alternative splicing, rare transcripts, and do not effectively discriminate between closely related *Ly49* gene transcripts. In order to obtain a more precise determination of all *Ly49* transcripts present in mature splenic NK cells, RNA was isolated from freshly isolated Ly49G or Ly49I-expressing splenic NK cells, to avoid artifacts associated with culture of NK cells in cytokines. The Ly49G-specific monoclonal antibody 4D11<sup>14</sup> and the Ly49C/I-specific monoclonal 5E6<sup>15</sup>, were used to sort 4D11-positive/5E6-negative versus 5E6-positive/4D11-negative NK cell subsets from C57BL/6 mice (Figure 1). These anti-Ly49 antibodies were chosen due to their ability to recognize a substantial fraction of the NK cells present in C57BL/6 spleen (50% of NK for 4D11, 48% for 5E6). The subsets obtained with this combination of antibodies would theoretically represent licensed Ly49C/I<sup>+</sup> NK cells that bind to the MHC H-2b present in C57BL/6 and unlicensed Ly49G<sup>+</sup> cells that do not bind to H-2b<sup>16, 17</sup>. However, the 5E6 antibody fails to recognize Ly49C in C57BL/6 due to the strong cis interaction of Ly49C with H-2b on the NK cell<sup>18, 19</sup>. 5E6 was shown to recognize Ly49C in BALB/c mice that express H-2d MHC, which is not a strong Ly49C ligand<sup>20</sup>. FACS analysis of C57BL/6 NK cells with the Ly49I-specific YLI-90 antibody together with 5E6 revealed a coincident staining pattern, whereas use of the Ly49C-specific 4LO3311 antibody identified the Ly49C-expressing subset<sup>18</sup>. Therefore, the subsets studied using the 4D11 and 5E6 antibodies in C57BL/6 mice are in fact Ly49G<sup>+</sup>/Ly49I<sup>-</sup> (G<sup>+</sup>/I<sup>-</sup>) and Ly49I<sup>+</sup>/Ly49G<sup>-</sup> (I<sup>+</sup>/G<sup>-</sup>) and will be referred to as such in this study. The complete lack of Ly49C recognition by the 5E6 antibody in C57BL/6 mice was confirmed by the nearly identical levels of *Ly49c* transcripts in the I<sup>+</sup>/G<sup>-</sup> versus the G<sup>+</sup>/I<sup>-</sup> samples (Table 1). The partial masking of Ly49I by the H-2K<sup>b</sup> ligand present on the surface of C57BL/6 NK cells is also suggested by the relatively low enrichment of *Ly49i* transcripts (~14 fold) in the I<sup>+</sup>/G<sup>-</sup> population compared to the high enrichment of *Ly49g* transcripts (~87 fold) in the G<sup>+</sup>/I<sup>-</sup> cells. Interestingly, transcripts for the *Ly49f* gene were enriched approximately 1.8 fold in the G<sup>+</sup>/I<sup>-</sup> population, in agreement with previous results from gene array studies that compared unlicensed NK cells to licensed NK cells, and found that *Ly49f* was the only gene up-regulated in unlicensed NK cells in all mouse models tested<sup>21</sup>. The G<sup>+</sup>/I<sup>-</sup> cells studied here are not a pure population of unlicensed cells, due to the presence of Ly49C-expressing cells that strongly recognize H-2K<sup>b</sup>, thus accounting for the modest enrichment of *Ly49f* transcripts. The high enrichment of Ly49G-expressing cells does however reveal some additional genes associated with this subset. Table 2 lists gene transcripts that were enriched > 2 fold in the G<sup>+</sup>/I<sup>-</sup> NK cells. The modest level of enrichment for these genes likely reflects their expression by relatively small subsets of G<sup>+</sup>/I<sup>-</sup> cells, such as the presence of thymus-derived NK indicated by the enrichment of IL7r-alpha, CD3-gamma, and CD3-delta transcripts<sup>22</sup>. It is unlikely that this is due to Ly49G-expressing T cells, since there was no detectable T cell contamination in the sorted populations shown in

Figure 1. The relative enrichment of these thymic NK markers in the  $G^+/I^-$  subset is likely due to the significantly higher percentage of thymus-derived NK that express Ly49G (15%) versus Ly49I (2%)<sup>22</sup>. The high level of enrichment of CD3-epsilon (~14 fold) is consistent with previous reports of intracellular expression of CD3-epsilon by activated NK cells<sup>23</sup>. The 2.5 fold enrichment of *Ly49a* transcripts in the  $G^+/I^-$  subset is likely due to the low inhibitory signaling present in these cells, thus allowing a greater window of opportunity for receptors that have a lower probability of activation, such as the increased expression of *Ly49f* on unlicensed NK cells<sup>21</sup>.

### Ly49 expression is not associated with Pro1 transcription

To directly assess if Pro1 transcripts can be found in mature Ly49-expressing NK cells, the RNA sequence data spanning the complete *Ly49* gene cluster was analyzed in detail, including a survey of individual sequences to identify novel transcripts that are not annotated in the reference mouse genome. Figure 2 shows a summary of *Ly49g* and *Ly49i* sense transcripts detected by RNA sequencing of freshly isolated Ly49G or Ly49I-expressing splenic NK cells. The number of spliced RNA sequences spanning 2 exons as detected by Sashimi analysis are shown. The majority of *Ly49i* transcripts originated within exon -1b, as previously reported by Gays *et al.*<sup>12</sup>, whereas *Ly49g* transcripts originated primarily in exon 1, indicating that Pro2 is the dominate promoter in splenic NK cells. The partial masking of Ly49I by H-2b is suggested by the presence of a low level of Ly49I-coding transcripts in the  $G^+/I^-$  population (~5% of the transcript level in  $I^+/G^-$ ), indicating that a subset of the Ly49I-expressing NK cells are not efficiently recognized by the 5E6 antibody. In contrast, potential Ly49G-coding RNAs were rare in the  $I^+/G^-$  population, and these RNAs did not exceed the level of non-translated Pro1 transcripts, indicating a lack of translatable *Ly49g* mRNAs in this population, consistent with the efficient detection of Ly49G by the 4D11 antibody.

A summary of the spliced 5' RNA sequences observed in inhibitory *Ly49* genes is shown in Figure 3. *Ly49* Pro1 transcripts containing exon -1a were only found for 2 genes, *Ly49e* and *Ly49g*. The complete lack of Pro1 transcripts in Ly49I-expressing cells indicates that Pro1 transcriptional activity is not required for gene expression. The presence of Pro1 transcripts from the *Ly49e* and *Ly49g* genes in Ly49-expressing splenic NK cells may be related to the ability of these genes to be activated in mature NK cells by stimulation with IL-2<sup>24, 25</sup>, suggesting that the Pro1 transcripts could be derived from cells that have received a stimulatory signal, and are in the process of gene activation. Notably, there is no significant difference in the level of Pro1 transcripts between  $G^+/I^-$  and  $I^+/G^-$  subsets, even though there are 87-fold more *Ly49g* transcript reads in the  $G^+/I^-$  population. The low level of *Ly49g* Pro1 transcription likely indicates a small population of cells that are in the process of activating the *Ly49g* gene. In the  $G^+/I^-$  cells, this would represent activation of a second *Ly49g* allele, as previously observed for purified monoallelic Ly49G<sup>B6</sup>-expressing NK cells after culture in IL-2<sup>25</sup>.

### Detection of novel *Ly49i* transcripts

RNA sequencing of Ly49I-expressing splenic NK cells revealed the unexpected presence of antisense *Ly49i* transcripts originating from the Pro2 and Pro3 regions spliced to two antisense exons upstream of Pro1 that will be referred to as antisense exons 2 and 3 (asEx2

and asEx3; Figure 3). Antisense transcripts were not detected for any other *Ly49* genes, indicating that the presence of antisense transcripts may be due to the use of a promoter upstream of exon -1b as the primary site of transcription in the *Ly49i* gene, as recently reported by Gays *et al*<sup>12</sup>. We have named this novel promoter Pro2<sup>i</sup>, and the transcriptional activity of this element is analyzed in the next section. To confirm the continuity of antisense transcripts identified by RNA sequencing, RT-PCR was performed to isolate antisense transcripts originating from promoters Pro2 and Pro3, as well as novel alternatively spliced sense transcripts originating in exon -1b and containing a previously unreported 132 bp non-coding exon (-1c) from both C57BL/6 and BALB/c mice. Novel *Ly49i* transcripts originating in exon -1b and containing exon -1c have been deposited in GenBank (KU645200-KU645202). The *Ly49i* Pro2 and Pro3 antisense transcripts utilized alternative exon 2 splice acceptor sites, resulting in either a 198 or 279 bp antisense exon 2 (GenBank#s KU645199, KU662345-KU662346). Pro2<sup>i</sup> transcripts were isolated from BALB/c spleen and bone marrow cDNA, indicating that Pro2<sup>i</sup> activity is not specific to the C57BL/6 *Ly49i* gene. Many of the antisense transcripts found in B6 mice could not be confirmed in BALB/c mice, since the splice acceptor for *Ly49i* antisense exon 3 is not present in the BALB/c *Ly49i* gene<sup>26</sup>. Only one *Ly49i* antisense transcript, asPro2-Ex2, was confirmed in BALB/c.

### Pro2<sup>i</sup> promoter activity

Given the large number of transcripts originating from exon -1b, and the previously characterized dominant start site in this region<sup>12</sup>, the region preceding exon -1b was investigated for the presence of a novel promoter element (Pro2<sup>i</sup>). To evaluate the promoter activity the Pro2<sup>i</sup> region, a series of pGL3 luciferase constructs spanning this sequence was generated (Figure 4a). The shortest fragment tested, R3, which ended at the dominant transcriptional start site<sup>12</sup>, showed weak promoter activity in the mature mouse NKT cell line EL-4 that expresses *Ly49A/G*<sup>27</sup> and demonstrates Pro2 promoter activity<sup>3</sup>, but not in the immature NK cell line LNK that lacks *Ly49* expression but supports Pro1 transcription<sup>3</sup> (Figure 4b). The low activity of the putative Pro2<sup>i</sup> promoter in EL-4 cells indicated that either this promoter has a cellular specificity that is distinct from the *Ly49a* and *Ly49g* Pro2 elements, or that a distal enhancer element might be required to produce substantial activity.

### The *Ly49i* Pro1 element does not exhibit enhancer activity

As it has recently been suggested that the distal upstream element Pro1 may act to enhance transcriptional activity of the downstream *Ly49* promoters<sup>13</sup>, a series of Pro1:Pro2<sup>i</sup> reporter constructs were generated to test for interaction of these two elements. To test the ability of Pro1 to enhance transcription from the novel promoter in its native configuration, we generated pGL3 constructs containing the full *Ly49i* sequence spanning the ~ 3.5 kb region from Pro1 to Pro2<sup>i</sup> and measured their activity in either LNK cells that support Pro1 transcription or EL-4 cells that support Pro2 transcription. The transcriptional specificity of these two cell lines was confirmed by RT-PCR of Pro1 transcripts from LNK cells and Pro2 transcripts from EL-4 (Figure 5a). Specific *Ly49g* Pro1 transcripts were detected in LNK, but not in EL-4. Although only weak signals were present in LNK cells for exon 2 of *Ly49a* and exon 1 of *Ly49g* that is preferentially used by Pro2 (Figure 2a), EL-4 clearly showed amplification of these exons, indicating the presence of Pro2 activity. The LNK and EL-4 cell lines are therefore appropriate lines for the *in vitro* study of Pro1 and Pro2

transcriptional activity. All of the full-length *Ly49i* Pro1-Pro2i constructs tested showed less activity than the background activity seen in the pGL3-Basic negative control (Figure 5b). This suggests that there is some inhibitory element in the intervening sequence between Pro1 and Pro2<sup>i</sup>. Alternatively, a high level of antisense Pro1 activity could produce antisense RNA spanning the luciferase gene, thus inhibiting its activity. To rule out this possibility, Pro1:Pro2<sup>i</sup> reporter constructs were linearized at a restriction enzyme site downstream of the luciferase gene prior to transfection. Linearized reporter constructs did not show any improvement in promoter activity (data not shown), therefore Pro1 antisense transcripts are not responsible for the decreased activity of Pro1:Pro2<sup>i</sup> reporter constructs.

To test for possible Pro1 enhancer function without the intervening *Ly49i* sequence between Pro1 and Pro2<sup>i</sup>, Pro1 was cloned into the distal enhancer site of the pGL3 vector. There was no significant difference in activity between the Pro2<sup>i</sup> constructs with and without the Pro1 element in the enhancer site of pGL3 in any cell line tested (compare Figure 4b with Figure 5c).

To test for possible interaction between Pro1 and Pro2<sup>i</sup> if the two elements were in close proximity to each other, PCR-SOEing<sup>28</sup> was used to generate Pro1-Pro2<sup>i</sup> fusion constructs. The Pro1-Pro2<sup>i</sup> fusion constructs showed no difference in activity in the mature EL-4 cell line, but greatly increased promoter activity, above either Pro2<sup>i</sup>-R3 or Pro1 alone, in the immature LNK cell line (Figure 5d). As Pro2<sup>i</sup>-R3 alone showed no activity in LNK, we performed a 5'RACE to confirm that transcripts were originating from the Pro2<sup>i</sup> element and that Pro2<sup>i</sup> was not acting as an enhancer for Pro1. The site of transcript initiation identified in the Pro1-Pro2<sup>i</sup> fusion corresponded to the major site identified by Gays *et al.*<sup>12</sup>. It appears that the Pro1 element can contribute to Pro2<sup>i</sup> activity in the immature LNK cell line, but as this relationship is dependent on the proximity of Pro1 and Pro2<sup>i</sup>, it does not function as an enhancer, and represents the addition of transcription factor binding sequences that conveys LNK cell-specific activity to the promoter complex.

### ***Ly49a* Pro2 promoter activity is independent of Pro1 in *Ly49*-expressing cells**

In order to identify additional *Ly49* genomic regions that may contribute to promoter activity, promoter activity of the full *Ly49a* Pro1/Pro2/Pro3 region was analyzed. Figure 6a shows the constructs generated that contained various combinations of the *Ly49* upstream elements. Figure 6b shows the activity of these constructs in the immature LNK cell line, and Figure 6c shows the activity in the mature *Ly49*-expressing EL-4 cells. The Pro2 promoter has been shown to be the major promoter used for the transcription of *Ly49a* in mature NK cells, as confirmed by the RNA sequence data presented in Figure 3. Constructs containing Pro2 and Pro3 had twice the activity of constructs containing Pro2 alone when studied in the EL-4 cell line. This enhancement was not observed in the LNK cell line. Although the Pro3 region had low activity when analyzed in isolation, it demonstrated substantial activity in EL-4 cells when combined with Pro2, possibly due to enhanced production of spliced transcripts originating from Pro2. Pro1 did not enhance Pro2/Pro3 activity in EL-4 cells, however it did increase the activity of constructs in LNK cells, consistent with Pro1 activity being limited to immature NK cells.



## Discussion

The current study represents the first comprehensive analysis of *Ly49* transcription in mature *Ly49*-expressing splenic NK cells. The expression of *Ly49* proteins represents the final stage of NK differentiation that determines their ability to detect missing self<sup>29</sup>. It is therefore important to study a population of purified *Ly49*-positive NK cells to identify transcripts associated with gene expression. The results obtained in this study confirm the activity of the previously identified *Ly49* promoters, and do not reveal any previously unknown promoter regions, however, novel spliced antisense transcripts originating from the *Ly49i* Pro2 and Pro3 promoters were detected.

With regard to the recent suggestion that Pro1 may function as an enhancer in mature NK cells, multiple lines of evidence presented here demonstrate that Pro1 transcripts are not associated with gene expression, and the Pro1 element likely plays no active role in protein expression in mature *Ly49* expressing cells. *In vitro* promoter assays suggest that Pro1 does not enhance downstream *Ly49* promoter activity. Luciferase reporter assays using large genomic fragments of the *Ly49a* gene revealed no enhancement of downstream promoter activity by Pro1 in its native genomic context in the *Ly49*-expressing EL-4 cell line. Some enhancement of transcriptional activity by Pro1 was seen in the LNK cell line, but it is likely due to translation of spliced Pro1 transcripts generated in these cells. RNA-sequencing analysis of freshly isolated *ex vivo* *Ly49*-expressing cells shows that transcripts originating from Pro1, which would be expected if it were acting as a promoter/enhancer in these cells, are totally absent in most variegated *Ly49* genes and very rare in the genes where they are found.

An important difference between the current study and the recent results from Gays *et al.*<sup>13</sup> is the use of freshly isolated, *Ly49*-expressing *ex vivo* NK cells for the analysis of *Ly49* gene transcription. The purified NK cells used by Gays *et al.* were not selected for *Ly49* expression, and were cultured for 12 days in IL-2, and thus represent an activated NK cell population. The *Ly49g* gene has been shown to be activated during culture of NK cells in IL-2, as has the *Ly49e* gene<sup>23, 24</sup>. In addition, *Ly49g* Pro1 transcripts were highly induced by treatment of mice with IL-2, and this was correlated with a rapid expansion of *Ly49G*<sup>+</sup> NK cells<sup>30</sup>. Therefore, the detection of Pro1 transcripts from these genes in purified NK cells cultured in IL-2 by Gays *et al.* is consistent with a role for Pro1 transcripts in the initial opening of the downstream Pro2 and Pro3 promoter region, resulting in *Ly49* gene expression by mature NK cells. Furthermore, the use of sorted *Ly49*-expressing cells in the current study ensured that only mature NK cells that are producing *Ly49* protein were assayed, and not immature NK that are in the process of activating the *Ly49* genes.

Paradoxically, although the Gays *et al.* study detects Pro1 forward transcripts in multiple cell lines, they suggest that there is little to no Pro1 forward transcriptional activity, and very strong reverse activity. In addition, RT-PCR experiments revealed that in all cases where Pro1 forward transcripts were detected, reverse transcripts were detected at a lower level<sup>13</sup>. This may be due to an inherent instability of the non-coding antisense transcript, however it is important to note that very high levels of Pro1 forward transcripts are detected, in contrast to the results obtained with *in vitro* reporter assays. Several possible factors that may

contribute to this discrepancy are as follows: 1) backbone sequences in the pGL series of reporter plasmids can affect activity, and we have chosen to use the pGL3 vector since we have found that the modifications made to reduce background transcriptional activity in the pGL4 vector had the opposite effect in the human and mouse NK cell lines we study; 2) changing the relative amount of flanking sequence in bidirectional promoter systems will change the relative strength of the competing promoters, and we have chosen core promoter fragments that have relatively balanced forward and reverse activity in order to study the switching properties; 3) the promoter activities in the Gays *et al.* study are reported relative to a very strong promoter, making Pro1 forward activity seem inconsequential; 4) Pro1 forward transcriptional activity is decreased or lost after extended periods of culture of the LNK line, making it important to use early passage cells for promoter analysis.

The model of Pro1 function suggests that forward transcripts originating from this element traverse the downstream promoters, displacing histones and allowing access of transcription factors required to activate the gene. The opening of the downstream promoter region may not require high levels of forward transcripts. The relatively low promoter activity found in *Ly49* Pro1 is comparable to the activities detected in distal *KIR* promoter elements that have been associated with gene activation<sup>31, 32</sup>.

No Pro1 transcripts were found in mature *Ly49*-expressing NK cells for the remaining variegated inhibitory genes, *Ly49a*, *Ly49c*, *Ly49i*, and *Ly49j*. This supports the hypothesis that Pro1 activity is important for the process of gene activation but does not play a role in the expression of the *Ly49* protein by mature NK cells. However, it is possible that the Pro1 element plays a role in maintaining an open chromatin configuration in a transcription-independent manner, and this would not be detected by *in vitro* reporter assays.

Initial studies of the specificity of the Pro1 promoter were performed before the antisense activity of the region was known. The extensive work of Gays *et al.* shows that reverse Pro1 activity is substantial and present in many cell types<sup>13</sup>. Conversely, the forward activity detected is weaker and more restricted. These findings are consistent with a model in which forward transcription from the Pro1 element is required for opening of the downstream regions required for gene expression. The production of reverse transcripts represents the default “off” state, and therefore may not be as tightly regulated as forward transcription.

It remains unclear whether the rare antisense transcripts detected originating from the *Ly49i* Pro2 and Pro3 regions play any functional role in gene regulation at any point in NK development or whether they are merely a consequence of an inability to transcribe efficiently in the forward direction due to the competition from the upstream Pro2<sup>i</sup> element<sup>33</sup>. Studies of the human transcriptome have revealed that approximately 8% of promoters are bidirectional with start sites separated by less than 300 bp<sup>34</sup>. It may be that many more promoters have the capacity to transcribe in the antisense direction, but the dominant function of factors generating sense transcripts prevents antisense transcription, and inhibition of sense transcription is required to reveal antisense activity. The ability of upstream promoters to inhibit transcription from downstream promoters provides an explanation for the silencing of Pro1 in mature NK. Although Pro1 transcripts are required



to open up the Pro2/Pro3 region of the gene, their continued presence would inhibit transcription factor binding to these promoters and reduce expression.

In summary, the data presented here confirm the immature NK cell-specificity of the Pro1 element and show that for each variegated *Ly49* gene, expression can occur in the absence of Pro1 transcripts. It will be of interest to determine the exact molecular events that determine the “window of opportunity” for *Ly49* gene activation and how they affect Pro1 activity.

## Materials and Methods

### Animals

C57BL/6 and BALB/c mice were maintained and bred in the NCI Frederick animal Breeding Facility. Animal care was provided in accordance with the procedures in, “A Guide for the Care and Use of Laboratory Animals”. Ethical approval for the animal experiments detailed in this manuscript was received from the Institutional Animal Care and Use Committee (Permit Number: 000386) at NCI-Frederick.

### RNA-Seq library preparation and sequencing

For each of 3 independent experiments, single cell suspensions were prepared from the spleens of 20 C57BL/6Ncr mice. NK cells were initially enriched using the MACS NK Cell purification system (Miltenyi Biotec, San Diego, CA) as described by the manufacturer. The Fc receptors of the resulting populations of enriched NK cells were blocked with 2.4G2 and the cells were stained with antibodies to CD3, NK1.1 (eBioscience Inc, San Diego CA), Ly49G2 (4D11), and Ly49C/I (5E6). CD3<sup>-</sup>, NK1.1<sup>+</sup>, Ly49G<sup>+</sup>, Ly49C/I<sup>-</sup> and CD3<sup>-</sup>, NK1.1<sup>+</sup>, Ly49G<sup>-</sup>, Ly49C/I<sup>+</sup> cells were sorted on a FACS Aria (BD Biosciences, San Jose, CA). Resulting populations were greater than 96% pure by post-sort analysis. Sorted NK cells were immediately processed for extraction of total RNA.

Stranded RNA-seq libraries were constructed from 0.4 µg total RNA using the TruSeq Stranded Total RNA Sample Prep Kits (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. The library insert sizes were approximately 175bp. Unique barcode adapters were applied to each library. Equal volumes of individual libraries were pooled and run on a MiSeq benchtop DNA sequencer (Illumina). The libraries were then repooled to equimolar concentrations based on the MiSeq demultiplexing results. The final pooled library was sequenced on a HiSeq2000 sequencer (Illumina) using TruSeq Version 3 chemistry and a bioinformatics pipeline built on RTA version 1.13.48 and CASAVA 1.8.2 software (Illumina). A minimum of 40 million 100 base read pairs were generated for each library. The RNA-seq dataset has been submitted to the GEO database, and are available under accession number GSE83153.

Raw Fastq files were aligned to mouse genome (mm10) using STAR (v. 2.3.0)<sup>35</sup>. Genes were subsequently counted using Rsubread<sup>36</sup>, and further analyzed for differential expression using limma-voom<sup>37</sup> to obtain the fold-change values shown in Tables 1 and 2. Splice junctions were visualized with the Sashimi function of the Integrated Genome Viewer (IGV-v2.3.67). Only uniquely mapped reads were included in the analyses.

## Cell collection, RNA Isolation, and cDNA Generation

Bone marrow and spleen cells were collected from two C57BL/6 (B6) and two BALB/c mice. Spleens were nicked with a pair of scissors to puncture the outer capsule and were then dissociated into a single cell suspension using a Dounce homogenizer. Bone Marrow was collected by cutting the ends of the femur and tibia bones and flushing out the marrow with phosphate buffered saline using a 23 gauge needle. Red blood cells were removed using ACK lysing buffer (Lonza, Walkersville, MD, USA) and NK cells were enriched by removal of non-NK cells using the EasySep Mouse NK Cell Enrichment Kit (STEMCELL Technologies, Vancouver, BC, Canada). RNA was extracted from the NK enriched cells using the Qiagen RNeasy Plus Mini Kit with an additional on-column DNase I digest using an RNase-Free DNase Set (Qiagen, Valencia, CA, USA) to reduce DNA contamination. cDNA copies of RNA transcripts were synthesized from isolated RNA with the TaqMan Reverse Transcription Reagents Kit (Applied Biosystems, Carlsbad, CA, USA) using the included random hexamer primers.

## Ly49i Transcript identification by RT-PCR

PCR of cDNA was used to isolate copies of transcripts from Pro2<sup>i</sup> using a Pro2<sup>i</sup> exon forward primer (5'-GGACTTTC AATCTGTCTTTGCTG) and Exon 3 reverse primer (5'-GAGTTGCCAGGATACTGAACAC). Rare antisense (as) transcripts were isolated using a nested PCR scheme first using a set of outer primers: asPro2 forward 1 (5'-GAAGATAGAGAAGACACACTCCTG), asPro3 forward 1 (5'-CAAAAACCCTGACATGGACTGATCC), asExon3 reverse 1 (5'-GTATAGTCATGTGTAGTTTCCTGTG) and as Exon2 reverse (5'-CCTCATGACTAAGGATGCTGAAC). The ChargeSwitch PCR Clean-Up Kit (Invitrogen, Carlsbad, CA, USA) was used to remove these primers from the products of first round of the nested PCR and these products were then used as the template for a second round of PCR using an inner primer set: asPro2 forward 2 (5'-GAAGACACACTCCTGCAGAGAGG), asPro3 forward 2 (5'-GGACTGATCCCAATTTCCATCAC), asExon3 reverse 2 (5'-CTGTGATCTTCAGTTTTGAAGTGG), and the same asExon2 reverse primer as the first round. Extension steps of PCRs for antisense transcripts were performed at 65°C to prevent the polymerase from prematurely detaching from a long poly-A region in antisense exon 2. The identities of transcripts were confirmed by cloning PCR products into the TOPO TA Cloning PCR 2.1 vector (Invitrogen) and sequencing.

## Ly49 Pro1 and Pro2 transcript identification in LNK and EL-4 cell lines

Total cellular RNA was isolated from LNK or EL-4 cells with the RNeasy Plus Mini Kit (Qiagen), and further purified using DNase I according to the manufacturer's instructions. cDNA was synthesized using Random Hexamer primer with the TaqMan® Reverse Transcription Reagents Kit (Applied Biosystems). PCR was performed with primers in exons -1a and -1b that are specific for the Pro1 transcripts of *Ly49a* or *Ly49g*, and primers in exons 1, 2, and 3 to detect Pro2 transcripts. *Ly49g* exon 1 is primarily found in Pro2 transcripts, but a low level (<4%) of Pro1 transcripts contain this exon (Figure 2a). Primers used were: *Ly49a* Pro1-Forward, 5'-GTCCAAGGGTGTGACTGGAAGG; *Ly49a* Pro1-

Reverse, 5'-GAGAAGTGAGGACTTTGTAGTG; Ly49a Exon2-Forward, 5'-GCAGAAACAAGTGAGACCTGAGGAG; Ly49a Exon3-Reverse, 5'-CCAACACTGAAACAGCTACCAGAAG; Ly49g Pro1-Forward, 5'-CAAGTGATCAGCCTATTCTTGTG; Ly49g Pro1-Reverse, 5'-CTTGTGTGAGTTTTGTACTTCAG; Ly49g Exon1-Forward, 5'-TTCTCCACAGGAATCACTTCTCAG; Ly49g Exon2-Forward, 5'-GAGTCTTCAAGGTTGCAGAACTAG; Ly49g Exon3-Reverse, 5'-GAGCTTCCAGGGGACTGAATACTC; Rps15-Forward, 5'-CCGAAGTGGAGCAGAAGAAG; Rps15-Reverse, Rev 5'-CTCCACCTGGTTGAAGGTC. Amplification was carried out using the ZymoTaq™ DNA Polymerase (Zymo Research, Irvine, CA) at 95°C for 10 minutes, and 38 cycles at 95°C for 15 seconds, 58°C for 45 seconds and 72°C for 20 seconds in a total volume of 50 µl in a SimpliAmp™ Thermal Cycler (Applied Biosystems). Products were separated on a 1% agarose gel stained with ethidium bromide and run for 90 minutes at 100 volts in 0.5x TBE buffer, then visualized under UV light.

### Generation of promoter constructs

Fragments of progressively shorter length spanning the Pro2<sup>i</sup> region were generated by PCR using a forward primer (5'-CACTGAACTGTACCCTCAATCC) and a set of reverse primers: Pro2<sup>i</sup> reverse 1 (5'-GTTGATTTTTAGAGAGTAGATGAGGTG), Pro2<sup>i</sup> reverse 2 (5'-GTGATGAAAATTGTTGGAAAGAAG), Pro2<sup>i</sup> reverse 3 (5'-CAAGTAATTGTCTTACCAGATGCTAGG) from a template plasmid generated from a previous study of the Ly49i region (GenBank AF173846)<sup>5</sup>. The *Ly49i* Pro1 construct was generated using primers Pro1 forward (5'-CATCTTCTCATTTCTTGCTCTC) and Pro1 reverse (5'-GCAGCAAGCTGCTCTTCTGCTCC). Fragments spanning the full Pro1-Pro2<sup>i</sup> region were generated using the Pro1 forward primer and the Pro2<sup>i</sup> reverse primer set. Pro1-Pro2<sup>i</sup> fusion constructs were generated using PCR splicing by overlap extension<sup>24</sup> using the Pro1 forward primer and Pro2<sup>i</sup> reverse primer set along with fusion primers Pro2<sup>i</sup> Fusion F (5'-GGACAGGAAGAGCAGCTTGCTGCCATCTGAGGACATTCTTAGCCTTC) and Pro1 Fusion R (5'-GAAGGCTAAGAATGTCCTCAGATGGCAGCAAGCTGCTCTTCTGCTCC).

*Ly49a* promoter constructs were generated by PCR of BAC DNA with the following primers: Pro1-F (5'-GAAGGACTATGTGTTTAGGC); Pro1-del-F (5'-CTGGAAGGTTTGAATGTGGG); Pro3-F (5'-CACCAGAACCACTTCTTGCT); Pro2-R (5'-AGCAAGAAGTGGTTCTGGTG); Pro3-R (5'-CTCAGTTCAAATGGTGCCTC).

Identities of fragments were confirmed by TA TOPO cloning PCR products into PCR 2.1 vector and sequencing. The genomic *Ly49* gene fragments were too large for TA TOPO cloning; the StrataClone PCR Cloning Kit (Agilent Technologies, Santa Clara, CA, USA) was used instead. Fragments confirmed by sequencing were transferred from PCR 2.1 or StrataClone vector to pGL3 Basic (Promega, Madison, WI, USA) luciferase reporter vector using either SacI/XhoI or XhoI/HindIII restriction enzymes depending on orientation. Pro1 enhancer constructs were generated by cloning Pro1 into the StrataClone vector and then transferring to pGL3 Basic using BamHI/SalI restriction enzymes.

## Cell culture

The mature mouse natural killer T (NKT) cell line EL-4 was cultured in RPMI-1640 medium supplemented with 10% Fetal bovine serum (FBS) and Penicillin-Streptomycin-Glutamine (PSG). Human Embryonic Kidney (HEK) 293T cells were cultured in DMEM with 10% FBS and PSG. The immature mouse NK cell line LNK was cultured in RPMI-1640 medium supplemented with 10% FBS, PSG, sodium pyruvate, non-essential amino acids, 2-mercaptoethanol, and 500 IU/mL IL-2.

## Transfections and luciferase assays

Cells were plated at a density of 50,000 cells per well in 24 well plates. Cells were co-transfected with a control pRL-SV40 *Renilla* Reporter Vector (Promega) to normalize luciferase readings. HEK293 cells and LNK cells were transfected using Lipofectamine 2000 (Invitrogen). LNK cells were transfected with 1000 ng of pGL3 construct and 50 ng of *Renilla* control using a ratio of 5  $\mu$ l Lipofectamine to 1  $\mu$ g DNA. 293 cells were transfected with 200 ng of pGL3 construct and 10 ng of *Renilla* control using a 0.6  $\mu$ l Lipofectamine to 1  $\mu$ g DNA for 293. EL-4 cells were transfected with 1500 ng pGL3 construct and 100 ng *Renilla* control using TrueFect-Max (United BioSystems, Herndon, VA, USA) at a ratio 2.5  $\mu$ l TrueFect to 1  $\mu$ g DNA. After 48 hours of incubation, cells were lysed and assayed for luciferase activity using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Measurement of the firefly luciferase activity of the *Ly49* promoter constructs was normalized relative to the activity of the *Renilla* luciferase produced by the pRL-SV40 control vector in order to control for differences in transfection efficiency, and each construct was tested in triplicate in at least three independent experiments

## 5' RACE of Pro1-Pro2<sup>i</sup> R3 fusion

LNK cells were transfected with the Pro1-Pro2<sup>i</sup> R3 fusion pGL3 construct as described above. RNA was isolated using the RNeasy Plus Mini Kit (Qiagen). 10  $\mu$ g of isolated RNA was used to carry out 5' rapid amplification of cDNA ends (5'RACE) using the FirstChoice RLM-RACE kit (Ambion, Austin, TX) following the included "5' RLM-RACE Protocol" using a 5' outer primer (5'-GCTGATGGCGATGAATGAACACTG) and a 5' inner primer (5'-CGCGGATCCGAACACTGCGTTTGCTGGCTTTGATG).

## Statistical analysis

T-tests were carried out using Microsoft Excel 2010 for Windows with the Analysis Toolpak add-in. A two-tailed paired T-test was used with a p value less than 0.05 considered significant.

## Acknowledgements


This project has been funded in whole or in part with federal funds from the National Cancer Institute (NCI), National Institutes of Health (NIH), under contract HHSN261200800001E. This research was supported in part by the Intramural Research Program of the NIH, NCI, Center for Cancer Research.

## References

1. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. *Nat Immunol.* 2008; 9:503–510. [PubMed: 18425107]
2. Lanier LL. NK cell recognition. *Annu Rev Immunol.* 2005; 23:225–274.
3. Saleh A, Makrigiannis AP, Hodge DL, Anderson SK. Identification of a novel Ly49 promoter that is active in bone marrow and fetal thymus. *J Immunol.* 2002; 168:5163–5169. [PubMed: 11994471]
4. Kubo S, Nagasawa R, Nishimura H, Shigemoto K, Maruyama N. ATF-2-binding regulatory element is responsible for the Ly49A expression in murine T lymphoid line, EL-4. *Biochim Biophys Acta.* 1999; 1444:191–200. [PubMed: 10023056]
5. Gosselin P, Makrigiannis AP, Nalewaik R, Anderson SK. Characterization of the Ly49I promoter. *Immunogenetics.* 2000; 51:326–331. [PubMed: 10803845]
6. Wilhelm BT, McQueen KL, Freeman JD, Takei F, Mager DL. Comparative analysis of the promoter regions and transcriptional start sites of mouse Ly49 genes. *Immunogenetics.* 2001; 53:215–224. [PubMed: 11398966]
7. Saleh A, Davies GE, Pascal V, Wright PW, Hodge DL, Cho EH, et al. Identification of probabilistic transcriptional switches in the Ly49 gene cluster: a eukaryotic mechanism for selective gene activation. *Immunity.* 2004; 21:55–66. [PubMed: 15345220]
8. Tanamachi DM, Moniot DC, Cado D, Liu SD, Hsia JK, Raulet. Genomic Ly49A transgenes: basis of variegated Ly49A gene expression and identification of a critical regulatory element. *J Immunol.* 2004; 172:1074–1082. [PubMed: 14707081]
9. Rouhi A, Gagnier L, Takei F, Mager DL. Evidence for epigenetic maintenance of Ly49a monoallelic gene expression. *J Immunol.* 2006; 176:2991–2999. [PubMed: 16493057]
10. Rouhi A, Brooks CG, Takei F, Mager DL. Plasticity of Ly49g expression is due to epigenetics. *Mol Immunol.* 2007; 44:821–826. [PubMed: 16750269]
11. Kubo S, Itoh Y, Ishikawa N, Nagasawa R, Mitarai T, Maruyama N. The gene encoding mouse lymphocyte antigen Ly-49: structural analysis and the 5'-flanking sequence. *Gene.* 1993; 136:329–331. [PubMed: 8294025]
12. Gays F, Koh AS, Mickiewicz KM, Aust JG, Brooks CG. Comprehensive analysis of transcript start sites in Ly49 genes reveals an unexpected relationship with gene function and a lack of upstream promoters. *PLoS ONE.* 2011; 6:e18475. [PubMed: 21483805]
13. Gays F, Taha S, Brooks CG. The Distal Upstream Promoter in Ly49 Genes, Pro1, Is Active in Mature NK Cells and T Cells, Does Not Require TATA Boxes, and Displays Enhancer Activity. *J Immunol.* 2015; 194:6068–6081. [PubMed: 25926675]
14. Mason L, Giardina SL, Hecht T, Ortaldo J, Mathieson BJ. LGL-1: a non-polymorphic antigen expressed on a major population of mouse natural killer cells. *J Immunol.* 1988; 140:4403–4412. [PubMed: 2453582]
15. Sentman CL, Hackett J, Kumar V, Bennett M. Identification of a subset of murine natural killer cells that mediates rejection of Hh-1<sup>d</sup> but not Hh-1<sup>b</sup> bone marrow grafts. *J Exp Med.* 1989; 170:191–202. [PubMed: 2664068]
16. Hanke T, Takizawa H, McMahan CW, Busch DH, Pamer EG, Miller JD, et al. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. *Immunity.* 1999; 11:67–77. [PubMed: 10435580]
17. Orr MT, Murphy WJ, Lanier LL. 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. *Nat Immunol.* 2010; 11:321–327. [PubMed: 20190757]
18. MacFarlane AW 4th, Yamazaki T, Fang M, Sigal LJ, Kurosaki T, Campbell KS. Enhanced NK-cell development and function in BCAP-deficient mice. *Blood.* 2008; 112:131–140. [PubMed: 18337558]
19. Forbes CA, Scalzo AA, Degli-Esposti MA, Coudert JD. Ly49C-dependent control of MCMV Infection by NK cells is cis-regulated by MHC Class I molecules. *PLoS Pathog.* 2014; 10:e1004161. [PubMed: 24873973]
20. Brennan J, Lemieux S, Freeman JD, Mager DL, Takei F. Heterogeneity among Ly-49C natural killer (NK) cells: Characterization of highly related receptors with differing functions and expression patterns. *J Exp Med.* 1996; 184:2085–2090. [PubMed: 8976165]


21. Guia S, Jaeger BN, Piatek S, Mailfert S, Trombik T, Fenis A, et al. Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance. *Sci Signal*. 2011; 4:ra21. [PubMed: 21467299]
22. Vosshenrich CA, García-Ojeda ME, Samson-Villéger SI, Pasqualetto V, Enault L, Richard-Le Goff O, et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. *Nat Immunol*. 2006; 7:1217–1224. [PubMed: 17013389]
23. Renard V, Ardouin L, Malissen M, Milon G, Lebastard M, Gillet A, et al. Normal development and function of natural killer cells in CD3 epsilon delta 5/delta 5 mutant mice. *Proc Natl Acad Sci USA*. 1995; 92:7545–7549. [PubMed: 7638228]
24. Gays F, Martin K, Kenefeck J, Aust JG, Brooks CG. Multiple cytokines regulate the NK gene complex-encoded receptor repertoire of mature NK cells and T cells. *J Immunol*. 2005; 175:2938–2947. [PubMed: 16116180]
25. Makrigiannis AP, Rousselle E, Anderson SK. Independent control of Ly49g alleles: implications for NK cell repertoire selection and tumor cell killing. *J Immunol*. 2004; 172:1414–1425. [PubMed: 14734717]
26. Anderson SK, Dewar K, Goulet ML, Leveque G, Makrigiannis AP. Complete elucidation of a minimal class I MHC natural killer cell receptor haplotype. *Genes Immun*. 2005; 6:481–492. [PubMed: 15931229]
27. Gays F, Unnikrishnan M, Shrestha S, Fraser KP, Brown AR, Tristram CM, et al. The mouse tumor cell lines EL4 and RMA display mosaic expression of NK-related and certain other surface molecules and appear to have a common origin. *J Immunol*. 2000; 164:5094–5102. [PubMed: 10799866]
28. Horton RM, Cai Z, Ho SM, Pease LR. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. *Biotechniques*. 1990; 8:528–535. [PubMed: 2357375]
29. Di Santo JP. Natural killer cell developmental pathways: a question of balance. *Annu Rev Immunol*. 2006; 24:257–286. [PubMed: 16551250]
30. Barao I, Alvarez M, Ames E, Orr MT, Stefanski HE, Blazar BR, et al. Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. *Blood*. 2011; 117:7032–7041. [PubMed: 21498673]
31. Stulberg MJ, Wright PW, Dang H, Hanson RJ, Miller JS, Anderson SK. Identification of distal KIR promoters and transcripts. *Genes Immun*. 2007; 8:124–130.
32. Cichocki F, Hanson RJ, Lenvik T, Pitt M, McCullar V, Li H, et al. The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element. *Blood*. 2009; 113:3245–3253. [PubMed: 18987359]
33. Martianov I, Ramadass A, Serra Barros A, Chow N, Akoulitchev A. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. *Nature*. 2007; 445:666–670. [PubMed: 17237763]
34. Trinklein ND, Aldred SF, Hartman SJ, Schroeder DI, Otilar RP, Myers RM. An abundance of bidirectional promoters in the human genome. *Genome Res*. 2004; 14:62–66. [PubMed: 14707170]
35. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*. 2013; 29:15–21. [PubMed: 23104886]
36. Liao Y, Smyth GK, Shi W. The subread aligner: fast, accurate and scalable read mapping by seed and vote. *Nucleic Acids Res*. 2013; 41:e108. [PubMed: 23558742]
37. Law CW, Chen Y, Shi W, Smyth GK. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol*. 2014; 15:R29. [PubMed: 24485249]






**Figure 1.**

Purity of sorted NK cell populations. Flow cytometry analysis of a representative experiment of 3 independent purifications and sorts performed. Populations were live-gated based on scatter, and analyzed before sorting (Pre-sort; upper panels) or after sorting (middle and lower panels) with antibodies recognizing NK1.1, CD3, Ly49G2 (4D11), and Ly49I (5E6) as noted. Purity of NK1.1+/CD3- cells (NK purity) is shown in the left column. Ly49 expression profiles (Ly49 expression) are shown in the right column. Purity of sorted 5E6+ve/4D11-ve (middle) and 4D11+ve/5E6-ve (bottom) populations are shown in the lower rows. Percentages represent the percent of live cells (left column) or percent of gated NK1.1+/CD3- cells observed with the antibodies (right column).



**Figure 2.**

Evaluation of Pro1, Pro2 and Pro3 transcription in  $G^+/I^-$  versus  $I^+/G^-$  splenic NK cells. The exon structures of the 5' region of the *Ly49g* and *Ly49i* genes are shown, with exons depicted as gray boxes, and promoter regions shown as thin black rectangles with the name of the exon or promoter element listed underneath. The arched lines containing numbers indicate the number of RNA sequences found that span the two exons linked by the line. Numbers are the average of three separate cell-sorting experiments. (a) *Ly49g* transcripts detected in either sorted  $G^+/I^-$  NK cells (*Ly49G*<sup>+ve</sup> NK, upper panel), or  $I^+/G^-$  NK cells (*Ly49I*<sup>+ve</sup> NK, lower panel). (b) *Ly49i* transcripts detected in either sorted  $I^+/G^-$  NK cells (*Ly49I*<sup>+ve</sup> NK, upper panel), or  $G^+/I^-$  NK cells (*Ly49G*<sup>+ve</sup> NK, lower panel).

**Figure 3.**

*Ly49* Pro1 transcripts are not associated with gene expression in mature NK cells. A schematic depicting all of the 5' *Ly49* exons revealed by RNA sequencing analysis is shown. Antisense exons are shown as red rectangles. The first antisense exons originating from either Pro2 or Pro3 are labeled  $\alpha S1^2$  and  $\alpha S1^3$  respectively. The second and third antisense exons are labeled  $\alpha S2$  and  $\alpha S3$ . The first 4 exons contained in *Ly49* Pro2 transcripts are shown as labeled green rectangles. Upstream exons derived from either Pro1 or Pro2<sup>i</sup> are shown as labeled light blue rectangles. The exon labeled -1a is the first exon of Pro1 transcripts. The exon labeled -1b<sup>1</sup> is the upstream exon found in *Ly49c* transcripts, whereas the exon labeled -1b<sup>2</sup> is used by *Ly49g* Pro1 transcripts and is the first exon of Pro2<sup>i</sup> transcripts. Exon -1c is an alternative exon used by some Pro2<sup>i</sup> transcripts. The table below lists spliced exons observed for either the G<sup>+</sup>/I<sup>-</sup> (*Ly49G*<sup>+</sup>ve) or I<sup>+</sup>/G<sup>-</sup> (*Ly49I*<sup>+</sup>ve) NK cell populations. Numbers listed are the average number of events from 3 independent cell-sorting experiments.

**a**

Pro2<sup>i</sup> F

CACTGAACTGCACCCTCAATCCAGTGAAGTGTCTGAAGTATTGAGCATGTGCAGCCTCACT  
 AGTAATGTGCACATCAATAGCTTTCAATGGAGGGTGATTGATGCAAAAATCAGCTTTCACCT  
 TATATGGAATAAAAAGTATATCTTGGAAACAATTTGAGTGATCATGTCTCCATGTTCCAATGT  
 GGAAGCAGTTTCATGAAATTTGGAGTTTAAAGTACCCAGATCATAAAATCCAGCCAATTC  
 AGCATAAATGGTGGATACATTAGAGAGGAGGTTGCAGCAATATGGGAAAACTTTTCTATA  
 GGACATCTGAGGACATTCCTAGCCTTCATGTTGGTGGAAAGGTAGTGGTCTGGTAGGTTTATA  
 AATTTTATGAAGTTTTTATCTGCCAGTGACAGGATGTTTGTCTGACACAGGTTATTTATAG

\*

GGCTAAACCTAGCATCTGGTAAAGCAATTACTTGTTAGATCCACAAAACACAAAGTCTCT


Pro2<sup>i</sup> R3 (468 bp)

CTTCTCGGACTTTCAAATCTGTCTCTGTGAAACAGCTTCTTTCCAACAATTTTCATCAGAA


Pro2<sup>i</sup> R2 (556 bp)

ACTAAAGGGCAAAACTCATAGAGGAAAAATCACCTCATCTACTCTAAAAATCAAC

Pro2<sup>i</sup> R1 (616 bp)




**Figure 4.** Promoter activity of *Ly49i* Pro2<sup>i</sup> constructs. **(a)** Sequences of Pro2<sup>i</sup> fragments. Underlined regions indicate sequence of primers used to generate each fragment. Bold nucleotides indicate TSSs identified by Gays et al. (12), with an asterisk signifying the dominant TSS. **(b)** Activity of pGL3 reporter constructs transfected into LNK, HEK293 (293), or EL-4 cells. The average fold activity of constructs relative to empty pGL3 vector from at least 3 independent experiments is shown. Error bars represent +/- 1 SEM, n=5.



**Figure 5.**

The Pro1 element does not possess enhancer activity. (a) Detection of Pro1 transcripts in LNK and Pro2 transcripts in EL-4. RT-PCR analysis of RNA purified from either LNK (left panel) or EL-4 (right panel) with *Ly49a* and *Ly49g* primers specific for Pro1 (*Ly49a/g* Pro1) or downstream exons is shown. Exon 2 (*Ly49a/g* Ex 2) of *Ly49a* or *Ly49g* is found in both Pro1 and Pro2 transcripts, however *Ly49g* exon1 (*Ly49g* Ex1) is preferentially used by Pro2 transcripts. Amplification of the ribosomal S15 protein (*Rps15*) is shown as a positive control. (b) Activity of constructs containing the full-length genomic sequence of the *Ly49i* gene from Pro1 to Pro2<sup>i</sup>, ending at each of the 3' primers shown in Figure 3 (*Ly49i* Pro1-Pro2<sup>i</sup>-FL-[R1-R3]) were transfected into LNK, HEK293 (293), or EL-4 cells. (c) Activity of constructs containing Pro1 in the pGL3 enhancer site and Pro2<sup>i</sup> in the promoter site. (d) Activity of Pro1-Pro2<sup>i</sup> fusion constructs with intervening sequence between Pro1 and Pro2<sup>i</sup> removed. The average fold activity of constructs relative to empty pGL3 vector from at least 3 independent experiments is shown. Error bars represent +/- 1 SEM, n=5.



**FIGURE 6.** *Ly49a* Pro2/Pro3 promoter activity is independent of Pro1 in Ly49-expressing cells. **(a)** Schematic of *Ly49a* promoter fragments analyzed. The upper line shows the complete *Ly49a* control region, with exons shown as numbered boxes, and promoter regions indicated by black boxes. The specific regions contained in each *Ly49a*-pGL3 reporter construct are shown below, with the name of the construct indicated to the right of each line. **(b)** Activity of constructs in LNK cells. **(c)** Activity of constructs in EL-4 cells. Blue-colored bars indicate constructs lacking the Pro1 region. The average fold activity of constructs relative to empty pGL3 vector from at least 3 independent experiments is shown. Error bars represent +/- 1 SEM, n=5.



**Table 1**Relative levels of Ly49 transcripts in G<sup>+</sup>/I<sup>-</sup> versus I<sup>+</sup>/G<sup>-</sup> NK cells.

Gene name	Protein	Function	Fold change	p value
<b>Klra9</b>	Ly49I	Inhibitory	-13.64	<b>1.89E-12</b>
<b>Klra14-ps</b>	Ly49N	Pseudogene	-1.01	<b>0.868</b>
<b>Klra5</b>	Ly49E	Inhibitory	1.20	<b>0.098</b>
<b>Klra3</b>	Ly49C	Inhibitory	1.24	<b>0.003</b>
<b>Klra8</b>	Ly49H	Activating	1.30	<b>0.007</b>
<b>Klra10</b>	Ly49J	Inhibitory	1.34	<b>0.030</b>
<b>Klra13-ps</b>	Ly49M	Pseudogene	1.63	<b>1.51E-04</b>
<b>Klra4</b>	Ly49D	Activating	1.77	<b>1.19E-05</b>
<b>Klra6</b>	Ly49F	Inhibitory	1.81	<b>3.70E-05</b>
<b>Klra1</b>	Ly49A	Inhibitory	2.47	<b>7.40E-07</b>
<b>Klra7</b>	Ly49G	Inhibitory	86.89	<b>5.91E-14</b>

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 2**Genes expressed 2-fold or greater in G<sup>+</sup>/I<sup>-</sup> versus I<sup>+</sup>/G<sup>-</sup> NK cells.

Gene	Protein	Function	Fold-change	p value
<b>Ikzf2</b>	IKAROS Family Zinc Finger 2 (Helios)	Transcription factor	2.10	2.17E-06
<b>Csf2</b>	GM-CSF	granulocyte/macrophage production/differentiation	2.17	1.31E-05
<b>Clip3</b>	CAP-GLY Domain Containing Linker Protein 3	links microtubules with cellular organelles.	2.01	1.31E-04
<b>Klra1</b>	Ly49a	Class I MHC receptor	2.47	7.40E-07
<b>Dll1</b>	Delta-Like 1	Notch ligand	2.31	9.82E-05
<b>Sox6</b>	SRY-box 6	Transcription factor	2.21	1.83E-05
<b>Ch11</b>	Cell Adhesion Molecule Homologous to L1CAM	Cell Adhesion	2.59	2.41E-05
<b>Gpr55</b>	G Protein-Coupled Receptor 55	Receptor for L-alpha-lysophosphatidylinositol	2.64	1.71E-05
<b>Slamf6</b>	SLAM Family Member 6	Coreceptor for NK cell activation	2.85	3.38E-06
<b>Cd3g</b>	CD3-gamma	TCR signaling	3.24	4.83E-06
<b>Il7r</b>	IL-7 Receptor Subunit Alpha	lymphocyte survival	3.96	8.11E-08
<b>Cd3d</b>	CD3-delta	TCR signaling	2.54	3.40E-05
<b>Dpysl5</b>	Dihydropyrimidinase-Like 5	Neuron differentiation, interacts with L1CAM	3.21	1.03E-05
<b>Cd3e</b>	CD3-epsilon	TCR signaling	13.77	5.87E-07
<b>Klra7</b>	Ly49g	Class I MHC receptor	86.89	5.91E-14